SFTA2, whose down-regulation indicates a poor prognosis in NSCLC patients, is related to increased inflammatory cells in some parts of the EMT, tumor heterogeneity, treatment efficiency, and the immune microenvironment of NSCLC [65]. Here, SFTA2 is linked to non-small cell lung carcinoma.